An evolving body of research has attempted to provide a better framework for the prediction of BCR progression, going beyond the clinical characteristics per se, which, like PSA, are disputable, and enriching them with a molecular landscape reflecting the clinical behavior of PC. This evidence concerns the gene BCR and pachyonychia congenita.